---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-021805"
form_type: "8-K/A"
ticker: "MASS"
cik: "0001555279"
company_name: "908 Devices Inc."
filed_at: "2025-03-07T23:59:59+00:00"
generated_at: "2026-05-25T03:39:09.069820+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# 908 Devices completes sale of desktop business to Repligen; pro forma shows $40.4M net loss from continuing ops in 2024

## Summary
- Sold desktop portfolio (Maverick, Rebel, Maven, Trace C2, ZipChip) to Repligen for ~$66M net upfront cash after transaction costs.
- Estimated gain on sale of $54.7M treated as discontinued operations; pro forma net loss from continuing ops improved to $(40.4M) in 2024 from $(72.2M) historical.
- Pro forma 2024 continuing ops revenue of $47.7M vs historical total $59.6M; loss per share from continuing ops $(1.19) vs historical $(2.12).
- Transaction includes supply agreement and transition services; estimated bonus of $0.65M to remaining employees.
- Cumulative translation adjustment of $1.1M released upon sale of 908 Devices GmbH.

## SEC filing metadata
- accession: 0001104659-25-021805
- form_type: 8-K/A
- ticker: MASS
- cik: 0001555279
- company_name: 908 Devices Inc.
- filed_at: 2025-03-07T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1555279/000110465925021805/0001104659-25-021805-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1555279/000110465925021805/tm258594d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-021805
- JSON: https://secwatch.observer/filing/0001104659-25-021805.json
- Plain text: https://secwatch.observer/filing/0001104659-25-021805.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.